Bill
Bill > HR2283
US HR2283
US HR2283CHANGE Act of 2019 Concentrating on High-value Alzheimer’s Needs to Get to an End Act of 2019
summary
Introduced
04/10/2019
04/10/2019
In Committee
04/11/2019
04/11/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
Modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports.Additionally, the Centers for Medicare and Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices.The Government Accountability Office also must conduct a study of policies that may accelerate progress in Alzheimer's disease research and enhance the quality of care for individuals diagnosed with Alzheimer's disease.
AI Summary
This bill, the Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2019 (CHANGE Act of 2019), aims to improve the detection, diagnosis, and treatment of Alzheimer's disease and related dementias under Medicare. Specifically, it expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated screening tools and referral of patients with detected impairment to appropriate diagnostic and support services. The bill also directs the Centers for Medicare and Medicaid Services to implement policies that incentivize providers to utilize high-quality cognitive impairment diagnosis practices and address Alzheimer's risk factors. Additionally, the Government Accountability Office must conduct a study on regulatory and legislative changes that could accelerate Alzheimer's disease research and enhance the quality of care for those diagnosed with the disease.
Committee Categories
Business and Industry, Health and Social Services
Sponsors (48)
Linda Sánchez (D)*,
Nanette Barragán (D),
Joyce Beatty (D),
Judy Chu (D),
Tom Cole (R),
Peter DeFazio (D),
Suzan DelBene (D),
Val Demings (D),
Michael Doyle (D),
Brian Fitzpatrick (R),
Jimmy Gomez (D),
Glenn Grothman (R),
Brian Higgins (D),
Joseph Kennedy (D),
Ro Khanna (D),
Adam Kinzinger (R),
Ann Kuster (D),
Darin LaHood (R),
Conor Lamb (D),
Susie Lee (D),
John Lewis (D),
Ted Lieu (D),
Zoe Lofgren (D),
Alan Lowenthal (D),
Brian Mast (R),
Doris Matsui (D),
Jim McGovern (D),
Cathy McMorris Rodgers (R),
Grace Napolitano (D),
Eleanor Holmes Norton (D),
Donald Payne (D),
Mark Pocan (D),
Bill Posey (R),
Jamie Raskin (D),
Kathleen Rice (D),
Lucille Roybal-Allard (D),
David Scott (D),
Mikie Sherrill (D),
Albio Sires (D),
Chris Smith (R),
Jason Smith (R),
Greg Stanton (D),
Haley Stevens (D),
Tom Suozzi (D),
Mark Takano (D),
Fred Upton (R),
Maxine Waters (D),
Peter Welch (D),
Last Action
Referred to the Subcommittee on Health. (on 04/11/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/2283/all-info |
| BillText | https://www.congress.gov/116/bills/hr2283/BILLS-116hr2283ih.pdf |
| Bill | https://www.congress.gov/116/bills/hr2283/BILLS-116hr2283ih.pdf.pdf |
Loading...